Oculis announced that its Phase 3 DIAMOND trials for OCS-01 eye drops in diabetic macular edema did not meet the primary endpoint of improved visual acuity after 52 weeks. However, the treatment showed significant and lasting reduction in retinal thickness, a secondary measure. The drug was well tolerated with no unexpected side effects. Oculis will not pursue FDA approval for OCS-01 for this condition but will focus on other drug candidates, including Privosegtor for optic nerve disorders and Licaminlimab for dry eye disease. The company maintains strong financial health with cash to fund operations through late 2029.
Ripple has pledged $300,000 to aid relief efforts after devastating flash floods hit Nepal and Tibet, causing hundreds of deaths and thousands missing. The funds will support food, clean water, and sanitation through partnerships with World Central K...
In the second quarter of 2026, markets recovered from earlier losses thanks to easing geopolitical tensions, strong corporate earnings, and improved investor sentiment. The Harbor Human Capital Factor US Large Cap ETF gained 11.82%, driven by top per...
Faruqi & Faruqi, LLP is urging investors who bought AEVEX Corp. securities between April 17, 2026, and April 17, 2026, to consider joining a federal securities class action lawsuit. The lawsuit alleges that AEVEX and its executives misled investors b...
Bitcoin's current bull cycle peak could be driven by increased institutional capital and ETF demand outside the United States, according to Cryptoquant founder Ki Young Ju. While the US has approved spot bitcoin ETFs since 2024, many countries like S...
Ethereum spot ETFs have attracted over $1.5 billion in inflows across 12 trading days since August 12, driven largely by BlackRock's clients purchasing $1.02 billion. Despite strong ETF demand, Ethereum's price is consolidating between $2,383 and $2,...
